SCHEMBL2337927

SCHEMBL2337927

COc1ccc(COc2c(C=CC(=O)O)ccc(OC)c2CC=C(C)C)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 4/20 0.48
▸ AKR1C2 P52895 3/20 0.48
▸ PTGER4 P35408 4/20 0.48
▸ PTGER2 P43116 4/20 0.48
▸ AKR1C4 P17516 2/20 0.48
▸ ABCB1 P08183 2/20 0.47
▸ HDAC8 Q9BY41 2/20 0.47
▸ PTGER3 P43115 3/20 0.45
▸ PTPN1 P18031 2/20 0.45
▸ TNFRSF1A P19438 1/20 0.45
▸ ALOX5 P09917 1/20 0.45
▸ FFAR1 O14842 1/20 0.43
▸ PPARG P37231 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ MAOB P27338 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2337919 1.00 AKR1C3 (0.48) AKR1C3AKR1C2PTGER4PTGER2AKR1C4
SCHEMBL7783022 0.91 PTGER4 (0.55) AKR1C3AKR1C2PTGER4PTGER2AKR1C4
SCHEMBL2336941 0.91 PTGER4 (0.55) AKR1C3AKR1C2PTGER4PTGER2AKR1C4
SCHEMBL2336935 0.91 PTGER4 (0.55) AKR1C3AKR1C2PTGER4PTGER2AKR1C4
SCHEMBL2334495 0.91 PTGER4 (0.48) AKR1C3AKR1C2PTGER4PTGER2AKR1C4
SCHEMBL2340914 0.91 PTGER4 (0.48) AKR1C3AKR1C2PTGER4PTGER2AKR1C4
SCHEMBL2340918 0.91 PTGER4 (0.48) AKR1C3AKR1C2PTGER4PTGER2AKR1C4
SCHEMBL2334504 0.91 PTGER4 (0.48) AKR1C3AKR1C2PTGER4PTGER2AKR1C4
SCHEMBL12300021 0.91 AKR1C3 (0.48) AKR1C3AKR1C2PTGER4PTGER2AKR1C4
SCHEMBL7776748 0.89 HDAC8 (0.62) ABCB1HDAC8PTPN1TNFRSF1AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2236503-B1 Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase NATUREWISE BIOTECH & MEDICALS CORP (TW) 2014-02-26 — — EP disclosed
US-8318801-B2 Cinnamic compounds and derivatives therefrom for the inhibition of histone deacetylase NATUREWISE BIOTECH & MEDICALS CORPORATION (TW) 2012-11-27 — — US disclosed
US-20110224294-A1 CINAMIC COMPOUNDS AND DERIVATIVES THEREFROM FOR THE INHIBITION OF HISTONE DEACETYLASE NATUREWISE BIOTECH & MEDICALS CORPORATION (TW) 2011-09-15 — — US disclosed
US-7994357-B2 Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase NATUREWISE BIOTECH & MEDICALS CORPORATION (TW) 2011-08-09 — — US disclosed
US-20100256401-A1 CINAMIC COMPOUNDS AND DERIVATIVES THEREFROM FOR THE INHIBITION OF HISTONE DEACETYLASE NATUREWISE BIOTECH & MEDICALS CORPORATION (TW) 2010-10-07 — — US disclosed
EP-2236503-A1 Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase NatureWise Biotech & Medicals Corporation (TW) 2010-10-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256401-A1 CINAMIC COMPOUNDS AND DERIVATIVES THEREFROM FOR THE INHIBITION OF HISTONE DEACETYLASE SMN1; SMN2, HDAC1, HDAC5 AKR1C3 1216/4885AKR1C2 764/4885PTGER4 4636/4885
US-20110224294-A1 CINAMIC COMPOUNDS AND DERIVATIVES THEREFROM FOR THE INHIBITION OF HISTONE DEACETYLASE SMN1; SMN2, HDAC1, HDAC5 AKR1C3 1216/4885AKR1C2 764/4885PTGER4 4636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback